Alpha-1 Antitrypsin Deficiency-Mediated Liver Toxicity: Why Do Some Patients Do Poorly? What Do We Know So Far?
Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation · 2020 · 7 (3) · 172-181
DOI: 10.15326/jcopdf.7.3.2019.0148 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, 2020. Verfasst von Marion Bouchecareilh. Beteiligte Einrichtung: National Institute of Health and Medical Research (INSERM), National Center for Scientific Research (CNRS), University Bordeaux, Bordeaux Research In…. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Institute of Health and Medical Research (INSERM), National Center for Scientific Research (CNRS), University Bordeaux, Bordeaux Research In Translational Oncology, BaRITOn, Bordeaux, France.
Zitieren
APA
Bouchecareilh, M. (2020). Alpha-1 Antitrypsin Deficiency-Mediated Liver Toxicity: Why Do Some Patients Do Poorly? What Do We Know So Far?. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, 7(3), 172-181. https://doi.org/10.15326/jcopdf.7.3.2019.0148
Vancouver
Bouchecareilh M. Alpha-1 Antitrypsin Deficiency-Mediated Liver Toxicity: Why Do Some Patients Do Poorly? What Do We Know So Far?. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2020;7(3):172-181. doi:10.15326/jcopdf.7.3.2019.0148
BibTeX
@article{Bouchecareilh2020,
author = {Bouchecareilh, Marion},
title = {Alpha-1 Antitrypsin Deficiency-Mediated Liver Toxicity: Why Do Some Patients Do Poorly? What Do We Know So Far?},
journal = {Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation},
year = {2020},
volume = {7},
number = {3},
pages = {172--181},
doi = {10.15326/jcopdf.7.3.2019.0148}
}
EUVIMED